Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $6 to $4.
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $6 to $4.